Brief: European Medicines Agency Grants Neurosense Sme Status

Neurosense Therapeutics

20/09/2023 14:23

Sept 20 (Reuters) - Neurosense Therapeutics Ltd
 NRSN.O :
    * EUROPEAN MEDICINES AGENCY GRANTS NEUROSENSE SME STATUS
    * NEUROSENSE THERAPEUTICS LTD - COMPANY PLANS TO ENROLL
PATIENTS
AT MULTIPLE SITES ACROSS EUROPE IN ITS PLANNED PHASE 3 PIVOTAL
ALS STUDY OF PRIMEC
    * NEUROSENSE THERAPEUTICS - EXPECTS TO COMMENCE A GLOBAL
PIVOTAL
PHASE 3 STUDY OF PRIMEC IN ALS IN 2024 WITH A VAST NUMBER OF
CLINICAL SITES IN EUROPE
    * NEUROSENSE THERAPEUTICS LTD - CLINICAL TOPLINE RESULTS
FROM
PARADIGM ARE EXPECTED AT END OF 2023

Source text for Eikon:  ID:nPncgP4Pqa 
Further company coverage:  NRSN.O 

 ((Reuters.Briefs@thomsonreuters.com))